Breast cancer genetics: Implications for clinical practice

Hematology/Oncology Clinics of North America

Volumn 14, Issue 3, 2000, Pages 705-725

  Olopade, Olufunmilayo I ^a,b   Fackenthal, James D ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; TAMOXIFEN;

BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL PRACTICE; EARLY DIAGNOSIS; GENE FUNCTION; GENE REARRANGEMENT; HORMONE SUBSTITUTION; HUMAN; MASTECTOMY; ONCOGENE NEU; OVARIECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0033945486     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70304-X     Document Type: Article

References (115)

1. American College of Obstetricians and Gynecologists Committee on Genetics ACOG committee opinion: Breast-ovarian cancer screening. Number 176, October 1996 Int J Gynaecol Obstet 56 1997 82 83
2. American Society of Clinical Oncology Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. Adopted on February 20, 1996 J Clin Oncol 1730 1996 6
3. D. Anderson W. Williams Familial cancer: Implications for healthy relatives Chaganti R. German J. Genetics in Clinical Oncology 1985 Oxford University Press New York
4. D.E. Anderson M.D. Badzioch Familial breast cancer risks. Effects of prostate and other cancers Cancer 72 1993 114 119
5. A. Arnold The cyclin D1/ PRAD1 oncogene in human neoplasia J Invest Med 43 1995 543 549
6. J. Baselga L. Norton J. Albanell Recombinant humanized anti- HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Res 58 1998 2825 2831
7. M.W. Beckmann D. Niederacher H.G. Schnurch Multistep carcinogenesis of breast cancer and tumour heterogeneity J Mol Med 75 1997 429 439
8. B.B. Biesecker M. Boehnke K. Calzone Genetic counseling for families with inherited susceptibility to breast and ovarian cancer JAMA 269 1993 1970 1974
9. J.D. Bitran B. Samuels Y. Trujillo Her2 /neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy Clin Can Res 2 1996 1509 1513
10. M. Bonilla M. Ramirez C.J. Lopez In vivo amplification and rearrangement of c-myc oncogene in human breast tumors J Natl Cancer Inst 80 1988 665 671
11. A. Borg B. Baldetorp M. Ferno ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer Cancer Lett 81 1994 137 144
12. Breast Cancer Linkage Consortium Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases Lancet 349 1997 1505 1510
13. J. Brugarolas T. Jacks Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair Nat Med 3 1997 721 722
14. M.F. Buckley K.J. Sweeney J.A. Hamilton Expression and amplification of cyclin genes in human breast cancer Oncogene 8 1993 2127 2133
15. W. Burke M. Daly J. Garber Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium JAMA 277 1997 997 1003
16. E. Chabner A. Nixon R. Gelman Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer J Clin Oncol 16 1998 2045 2051
17. V.R. Chazin M. Kaleko A.D. Miller Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor Oncogene 7 1992 1859 1866
18. E.B. Claus N. Risch W.D. Thompson Genetic analysis of breast cancer in the cancer and steroid hormone study Am J Hum Genet 48 1991 232 242
19. E.B. Claus N.J. Risch W.D. Thompson Age at onset as an indicator of familial risk of breast cancer Am J Epidemiol 131 1990 961 972
20. G.A. Colditz W.C. Willett D.J. Hunter Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study JAMA 270 1993 338 343
21. N. Collins R. McManus R. Wooster Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13 Oncogene 10 1995 1673 1675
22. F. Couch B. Weber Breast cancer Vogelstein B. Kinzler K. The Genetic Basis of Human Cancer 1998 McGraw-Hill New York 537 563
23. F.J. Couch M.L. DeShano M.A. Blackwood BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer N Engl J Med 336 1997 1409 1415
24. F.J. Couch L.C. Hartmann BRCA1 testing—Advances and retreats JAMA 279 1998 955 957
25. T. Crook L.A. Brooks S. Crossland p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1 - and BRCA2 -associated breast tumours Oncogene 17 1998 1681 1689
26. T. Crook S. Crossland M.R. Crompton p53 mutations in BRCA1 -associated familial breast cancer Lancet 350 1997 638 639
27. G. Deng L.C. Chen D.R. Schott Loss of heterozygosity and p53 gene mutations in breast cancer Cancer Res 54 1994 499 505
28. F.P. Di J.H. Pierce M.H. Kraus erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells Science 237 1987 178 182
29. M.L. Disis M.A. Cheever HER-2/ neu protein: A target for antigen-specific immunotherapy of human cancer Adv Cancer Res 71 1997 343 371
30. F. Eisinger L.D. Stoppa M. Longy Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer Cancer Res 56 1996 471 474
31. R.M. Elledge S.A. Fuqua G.M. Clark William L. McGuire Memorial Symposium. The role and prognostic significance of p53 gene alterations in breast cancer Breast Cancer Res Treat 27 1993 95 102
32. B. Fisher J.P. Costantino D.L. Wickerham Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 90 1998 1371 1388
33. D. Ford D.F. Easton D.T. Bishop Risks of cancer in BRCA1 -mutation carriers. Breast Cancer Linkage Consortium Lancet 343 1994 692 695
34. D. Ford D.F. Easton M. Stratton Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium Am J Hum Genet 62 1998 676 689
35. T.S. Frank S.A. Manley O.I. Olopade Sequence analysis of BRCA1 and BRCA2 : Correlation of mutations with family history and ovarian cancer risk J Clin Oncol 16 1998 2417 2425
36. J. Frisell E. Lidbrink L. Hellstrom Followup after 11 years—Update of mortality results in the Stockholm mammographic screening trial Breast Cancer Res Treat 45 1997 263 270
37. M.H. Gail L.A. Brinton D.P. Byar Projecting individualized probabilities of developing breast cancer for white females who are being examined annually J Natl Cancer Inst 81 1989 1879 1886
38. Q. Gao S. Neuhausen S. Cummings Recurrent germ-line BRCA1 mutations in extended African American families with early-onset breast cancer Am J Hum Genet 60 1997 1233 1236
39. J.P. Garne K. Aspegren G. Balldin Increasing incidence of and declining mortality from breast carcinoma. Trends in Malmo, Sweden, 1961–1992 Cancer 79 1997 69 74
40. J. Gudmundsson G. Johannesdottir J.T. Bergthorsson Different tumor types from BRCA2 carriers show wild-type chromosome deletions on 13q12-q13 Cancer Res 55 1995 4830 4832
41. L.C. Hartmann D.J. Schaid J.E. Woods Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer N Engl J Med 340 1999 77 84
42. M.A. Helvie M.A. Roubidoux B.L. Weber Mammography of breast carcinoma in women who have mutations of the breast cancer gene BRCA1 : Initial experience AJR Am J Roentgenol 168 1997 1599 1602
43. Hennipman A. van O.B. J. Smits Tyrosine kinase activity in breast cancer, benign breast disease, and normal breast tissue Cancer Res 49 1989 516 521
44. S.L. Hopper M.C. Soutney G.S. Dite Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study Cancer Epidemiol Biomarkers Prev 8 1999 741 747
45. K.F. Hoskins J.E. Stopfer K.A. Calzone Assessment and counseling for women with a family history of breast cancer. A guide for clinicians JAMA 273 1995 577 585
46. Y. Hosokawa A. Arnold Mechanism of cyclin D1 ( CCND1, PRAD1 ) overexpression in human cancer cells: Analysis of allele-specific expression Genes Chromosomes Cancer 22 1998 66 71
47. K.L. Hudson K.H. Rothenberg L.B. Andrews Genetic discrimination and health insurance: An urgent need for reform Science 270 1995 391 393
48. R.M. Hudziak J. Schlessinger A. Ullrich Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells Proc Natl Acad Sci U S A 84 1987 7159 7163
49. A. Husain G. He E.S. Venkatraman BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum (II) Cancer Res 58 1998 1120 1125
50. G.A. Lammie V. Fantl R. Smith D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1 Oncogene 6 1991 439 444
51. R.J. Lee C. Albanese R.J. Stenger pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells J Biol Chem 274 1999 7341 7350
52. K. Leitzel Y. Teramoto K. Konrad Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer J Clin Oncol 13 1995 1129 1135
53. D.K. Luttrell A. Lee T.J. Lansing Involvement of pp60c-src with two major signaling pathways in human breast cancer Proc Natl Acad Sci U S A 91 1994 83 87
54. H. Lynch Distinctive clinicopathologic features of BRCA1 -linked hereditary breast cancer Proceedings of the American Society of Clinical Oncology 13 1994 56
55. K.E. Malone J.R. Daling J.D. Thompson BRCA1 mutations and breast cancer in the general population: Analyses in women before age 35 years and in women before age 45 years with first-degree family history JAMA 279 1998 922 929
56. J.N. Marcus P. Watson D.L. Page Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage Cancer 77 1996 697 709
57. J.N. Marcus P. Watson D.L. Page BRCA2 hereditary breast cancer pathophenotype Breast Cancer Res Treat 44 1997 275 277
58. C.R. Mariani G. Merlo L. Frati Genomic alterations in human breast cancer: A review Tumori 75 1989 311 320
59. Y. Miki J. Swensen E.D. Shattuck A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 1994 66 71
60. T. Motokura A. Arnold Cyclins and oncogenesis Biochim Biophys Acta 1155 1993 63 78
61. E.A. Musgrove J.A. Hamilton C.S. Lee Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression Mol Cell Biol 13 1993 3577 3587
62. H.B. Muss A.D. Thor D.A. Berry c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer N Engl J Med 330 1994 1260 1266
63. B. Newman H. Mu L.M. Butler Frequency of breast cancer attributable to BRCA1 in a population-based series of American women JAMA 279 1998 915 921
64. National Institutes of Health Consensus Conference Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer JAMA 273 1995 491 497
65. K. Offit T. Gilewski P. McGuire Germline BRCA1 185delAG mutations in Jewish women with breast cancer Lancet 347 1996 1643 1645
66. K.A. Ottenhoff G. Rijksen van B.E. Characterization of protein tyrosine kinases from human breast cancer: Involvement of the c-src oncogene product Cancer Res 52 1992 4773 4778
67. T. Ouchi A.N. Monteiro A. August BRCA1 regulates p53-dependent gene expression Proc Natl Acad Sci U S A 95 1998 2302 2306
68. G. Parmigiani D. Berry O. Aguilar Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62 1998 145 158
69. G. Pauletti W. Godolphin M.F. Press Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization Oncogene 13 1996 63 72
70. M.D. Pegram A. Lipton D.F. Hayes Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment J Clin Oncol 16 1998 2659 2671
71. C.M. Phelan J.M. Lancaster P. Tonin Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families Nat Genet 13 1996 120 122
72. C.M. Phelan T.R. Rebbeck B.L. Weber Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus Nat Genet 12 1996 309 311
73. J.H. Pierce P. Arnstein E. DiMarco Oncogenic potential of erbB-2 in human mammary epithelial cells Oncogene 6 1991 1189 1194
74. R.J. Pietras M.D. Pegram R.S. Finn Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs Oncogene 17 1998 2235 2249
75. R.J. Pietras J.C. Poen D. Gallardo Monoclonal antibody to HER-2/ neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene Cancer Res 59 1999 1347 1355
76. M.S. Piver M.F. Jishi Y. Tsukada Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer. A report of the Gilda Radner Familial Ovarian Cancer Registry Cancer 71 1993 2751 2755
77. T.J. Powles Re: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J Natl Cancer Inst 91 1999 730
78. M.F. Press L. Bernstein P.A. Thomas HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas J Clin Oncol 15 1997 2894 2904
79. M.F. Press G. Hung W. Godolphin Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression Cancer Res 54 1994 2771 2777
80. K.I. Pritchard Is tamoxifen effective in prevention of breast cancer? Lancet 352 1998 80 81
81. T.R. Rebbeck A.M. Levin A. Eisen Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers J Natl Cancer Inst 91 1999 1475 1479
82. D.M. Reese D.J. Slamon HER-2/neu signal transduction in human breast and ovarian cancer Stem Cells 15 1997 1 8
83. M. Robson T. Gilewski B. Haas BRCA -associated breast cancer in young women J Clin Oncol 16 1998 1642 1629
84. J.S. Ross J.A. Fletcher The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy Stem Cells 16 1998 413 428
85. K. Rothenberg B. Fuller M. Rothstein Genetic information and the workplace: Legislative approaches and policy changes Science 275 1997 1755 1767
86. S. Saitoh J. Cunningham V.E. De p53 gene mutations in breast cancers in midwestern US women: Null as well as missense-type mutations are associated with poor prognosis Oncogene 9 1994 2869 2875
87. J.O. Schorge M.G. Muto W.R. Welch Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations J Natl Cancer Inst 90 1998 841 845
88. R. Scully J. Chen R.L. Ochs Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage Cell 90 1997 425 435
89. R. Scully J. Chen A. Plug Association of BRCA1 with Rad51 in mitotic and meiotic cells Cell 88 1997 265 275
90. L.G. Sheffield C-Src activation by ErbB2 leads to attachment-independent growth of human breast epithelial cells Biochem Biophys Res Commun 250 1998 27 31
91. D.J. Slamon G.M. Clark S.G. Wong Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/ neu oncogene Science 235 1987 177 182
92. D.J. Slamon W. Godolphin L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
93. M.L. Slattery R.A. Kerber A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database JAMA 270 1993 1563 1568
94. S.A. Smith D.F. Easton D.G. Evans Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome Nat Genet 2 1992 128 131
95. K. Somasundaram H. Zhang Y.X. Zeng Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1 Nature 389 1997 187 190
96. M.E. Stefanek K.J. Helzlsouer P.M. Wilcox Predictors of and satisfaction with bilateral prophylactic mastectomy Prev Med 24 1995 412 419
97. J.P. Struewing P. Hartge S. Wacholder The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews N Engl J Med 336 1997 1401 1408
98. J.P. Struewing P. Watson D.F. Easton Prophylactic oophorectomy in inherited breast/ovarian cancer families J Natl Cancer Inst Monogr 17 1995 33 35
99. S.V. Tavtigian J. Simard J. Rommens The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds Nat Genet 12 1996 333 337
100. S. Thorlacius G. Olafsdottir L. Tryggvadottir A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes Nat Genet 13 1996 117 119
101. S. Thorlacius S. Sigurdsson H. Bjarnadottir Study of a single BRCA2 mutation with high carrier frequency in a small population [see comments] Am J Hum Genet 60 1997 1079 1084
102. S. Thorlacius J.P. Struewing P. Hartge Population-based study of risk of breast cancer in carriers of BRCA2 mutation Lancet 352 1998 1337 1339
103. L.C. Verhoog C.T. Brekelmans C. Seynaeve Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351 1998 316 321
104. U. Veronesi P. Maisonneuve A. Costa Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study Lancet 352 1998 93 97
105. T.C. Wang R.D. Cardiff L. Zukerberg Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice Nature 369 1994 669 671
106. P. Watson J.N. Marcus H.T. Lynch Prognosis of BRCA1 hereditary breast cancer Lancet 351 1998 304 305
107. S.D. Weinstat M.J. Merino R.E. Manrow Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions Nat Med 1 1995 1257 1260
108. A.S. Whittemore G. Gong J. Itnyre Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: Results from three U.S. population-based case-control studies of ovarian cancer Am J Hum Genet 60 1997 496 504
109. P.A. Wingo L.A. Ries H.M. Rosenberg Cancer incidence and mortality, 1973–1995: A report card for the U.S Cancer 82 1998 1197 1207
110. R. Wooster G. Bignell J. Lancaster Identification of the breast cancer susceptibility gene BRCA2. Nature 378 1995 789 792
111. C. Wright S. Nicholson B. Angus Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer Br J Cancer 65 1992 118 121
112. W.R. Xing K.W. Gilchrist C.P. Harris FISH detection of HER-2/ neu oncogene amplification in early onset breast cancer Breast Cancer Res Treat 39 1996 203 212
113. X. Xu K.U. Wagner D. Larson Conditional mutation of Brcal in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation Nat Genet 22 1999 37 43
114. H. Zhang K. Somasundaram Y. Peng BRCA1 physically associates with p53 and stimulates its transcriptional activity Oncogene 16 1998 1713 1721
115. H. Zhang G. Tombline B.L. Weber BRCA1, BRCA2, and DNA damage response: Collision or collusion? Cell 92 1998 433 436